Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02229903 · ClinicalTrials.gov registry record · NA
An Evaluation of the Safety and Efficacy of the dTMS Treatment for OCD
A NA study, sponsored by Brainsway.
- Completed
- Registry status
- NA
- Development phase
- 100
- Enrollment target
NCT02229903: Completed NA study, sponsored by Brainsway.
NCT02229903 is a NA study that has completed, run by Brainsway. The registered enrollment target is 100 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02229903, a NA study, has completed, sponsored by Brainsway.
- COMPLETED
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and efficacy of the Deep TMS (DTMS) treatment in subjects with OCD. The device technology is based on the application of deep brain TMS by means of repetitive pulse trains at a predetermined frequency. The Brainsway DTMS study is a randomized, 10 week, double blind, multi-center trial comparing active DTMS treatment to sham treatment.
Primary Outcome
The primary objective of the study is to compare the change in Yale Brown Obsessive Compulsive Scale (YBOCS) scores from baseline to the 6 week (post-randomization) visit, between the two treatments groups.
Interventions
- DEVICE Sham Treatment
- DEVICE Active DTMS Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2014-09 |
| Est. Completion | 2017-06 |
| Phase | NA |
What the finished NCT02229903 record still lists
NCT02229903 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Sham Treatment is the first listed.
NCT02229903 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02229903 about?
NCT02229903 is a clinical study titled "An Evaluation of the Safety and Efficacy of the dTMS Treatment for OCD". The purpose of the study is to evaluate the safety and efficacy of the Deep TMS (DTMS) treatment in subjects with OCD. The device technology is based on the application of deep brain TMS by means of repetitive pulse trains at a predetermined frequency. The Brainsway DTMS study is a randomized, 10 we...
What is the current status of trial NCT02229903?
This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2014-09. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02229903?
The interventions under investigation include: Sham Treatment (DEVICE), Active DTMS Treatment (DEVICE).
Who is sponsoring clinical trial NCT02229903?
This trial is sponsored by Brainsway, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02229903's enrollment target sits among peer trials
100 840th of 2000 higher than 1,081 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia